Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite
this, the treatment options remain limited. Preclinical and preliminary clinical data suggest
that estrogen deficiency plays an important role in the pathology of steatosis, inflammation
and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD.
Post-menopausal women are a growing population with particularly high risk of NASH due to
their lack of estrogen. This study will examine the effect of estradiol on hepatic fibrosis
and fat in post-menopausal women with NASH.